BPC-157

What is BPC-157?

BPC-157 is a stable fragment of a protein (Body Protection Compound) naturally present in human gastric juice. The synthetic peptide is a chain of 15 amino acids.

It does not occur in this isolated form in nature; it was developed to concentrate the tissue-protective activity researchers observed in the parent compound.

Benefits and uses

What the research shows — most of it in animal models, which is the honest framing for BPC-157:

• Tendon, ligament, and muscle repair. The most-studied effect. BPC-157 promotes angiogenesis (new blood-vessel formation) and fibroblast activity, which speeds soft-tissue healing in animal injury models.
• Gut repair. Given its origin in gastric juice, BPC-157 has been studied for protecting and healing the gut lining, including in models of inflammatory bowel conditions and NSAID-induced damage.
• Inflammation. It modulates inflammatory signaling, which is part of why it’s used alongside injuries.
• Tissue protection. Research has looked at protective effects on a range of tissues, but human clinical data remains limited.

The gap between the volume of anecdote and the volume of human evidence is real. BPC-157 has a large following based on animal research and user reports; rigorous human trials are limited. State that plainly rather than overselling.

How it works

BPC-157 appears to act largely by promoting angiogenesis — the growth of new blood vessels into damaged tissue — and by upregulating growth-hormone receptor expression in injured tissue, which sensitizes the area to the body’s own repair signals.

It also interacts with the nitric-oxide pathway, which contributes to its effects on blood flow and tissue protection.

Dosage and administration

Typical protocols in the literature and clinical practice use subcutaneous injection near the injury site, though oral and intramuscular routes are also used.

Commonly cited ranges run 200–500 mcg per dose, once or twice daily, in cycles of 4–6 weeks. These are not official dosing guidelines — there is no FDA-approved BPC-157 product — and dosing should be set by the prescribing provider.

Reconstitution (mixing the lyophilized powder with bacteriostatic water) and drawing the right volume on an insulin syringe is where most people make errors.

For a peptide your clinician prescribed and an appropriate pharmacy prepared, use the peptide dosage calculator to convert the prescribed target dose into syringe units for your vial size.

Side effects and safety

BPC-157 has shown a favorable safety profile in animal studies, with low toxicity even at high doses. Reported effects in human use are generally mild — injection-site reactions, lightheadedness, fatigue, nausea.

The honest caveat: long-term human safety data does not exist. Anyone using BPC-157 should monitor liver enzymes and kidney function and work with a provider.

How to get BPC-157 in 2026

This is the question most searchers actually have. The status changed this year:

• For several years BPC-157 sat on the FDA’s Section 503A Category 2 list, which effectively blocked compounding pharmacies from preparing it.
• On April 15, 2026 the FDA removed BPC-157 (and 11 other peptides) from that Category 2 list.
• A Pharmacy Compounding Advisory Committee meeting on July 23–24, 2026 will evaluate whether BPC-157 should be formally added to the authorized bulk-substances list compounding pharmacies can use.

Until that process completes, do not treat the advisory review as approval. Products sold online “for research use only” are not approved, manufactured, or quality-controlled for human use, and buying them carries both quality and legal risk.